CClinicalTrials.gg
CompletedNCT03213327StayOKUpdated Jun 23, 2020

StayOK - an Innovative Measuring Instrument for the Early Identification and Treatment of Psychosocial Risks

An interventional study of StayOk web application in Mental Health Disorder, sponsored by Zurich University of Applied Sciences. Completed at 1 site in Switzerland. Open to participants aged 16 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-23.

Sponsored by Zurich University of Applied Sciences · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
174
Allocation
Not applicable
Ages
16 Years to 65 Years
Sex
All
01

Study summary

The validity and the sensitivity of different measures implemented in the web application StayOk are investigated. The measures are used primarily for the assessment and the early identification of psychosocial risks. Secondarily, the results of the assessment are applied to generate health-promoting advices for the user of the web application.

02

Conditions studied

  • Mental Health Disorder

Browse trials for

Keywords

  • mental health
  • assessment
  • health promotion
  • case management
  • health insurance
03

In context

Mental Disorders

2,107 studies on the registry are indexed under Mental Disorders; 416 are open to participants now.

This study's enrollment of 174 is above the median of 94 across 1,574 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Zurich University of Applied Sciences is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • at 16 years of age
  • mild to moderate psychological distress

Exclusion criteria

Exclusion Criteria:

  • serious cognitive impairment due to dementia or cerebrovascular insult
  • Insufficient knowledge of one of the following languages: German, French, Italian or English
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
174 participants (actual)

Study arms

  • Other
    Case management

    Case management program Utilization of the StayOk web application

    Device: StayOk web application

Interventions

  • DeviceStayOk web application

    Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices

06

What researchers measure

Primary outcomes

  1. Psychological distress

    The psychological distress is assessed by the Brief Symptom Inventory (BSI; Derogatis \& Melisaratos, 1983)

    Time frame: 0 week (first assessment)

  2. Work-related sense of coherence

    The work-related sense of coherence is assessed by the Work Sense of Coherence (W-SoC 9; Jenny et al., 2016)

    Time frame: 0 weeks

  3. Perceived self-efficacy

    This aspect is measure by the General Self-Efficacy Scale (GSE; Damásio et al., 2016)

    Time frame: 0 weeks

Secondary outcomes

  1. Effectiveness of health-promoting advices

    The effectiveness of the advices generated by the software is assessed by means of a self-developed questionnaire: Participants are inquired as to (1) whether they put in practice the advices and (2) how they evaluate the benefit of the applied advices and the consequent satisfaction.

    Time frame: 12 weeks after the first assessment

07

Study locations

1 site
  • Helsana
    Zürich, Switzerland
08

References and documents

Publications

  • Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983 Aug;13(3):595-605. PubMed 6622612 ↗
  • Jenny GJ, Bauer GF, Vinje HF, Vogt K, Torp S. The Application of Salutogenesis to Work. 2016 Sep 3. In: Mittelmark MB, Sagy S, Eriksson M, Bauer GF, Pelikan JM, Lindstrom B, Espnes GA, editors. The Handbook of Salutogenesis [Internet]. Cham (CH): Springer; 2017. Chapter 20. Available from http://www.ncbi.nlm.nih.gov/books/NBK435821/ PubMed 28590629 ↗
  • Damasio BF, Valentini F, Nunes-Rodriguez SI, Kliem S, Koller SH, Hinz A, Brahler E, Finck C, Zenger M. Is the General Self-Efficacy Scale a Reliable Measure to be used in Cross-Cultural Studies? Results from Brazil, Germany and Colombia. Span J Psychol. 2016 May 26;19:E29. doi: 10.1017/sjp.2016.30. PubMed 27225231 ↗

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03213327
Lead sponsor
Zurich University of Applied Sciences
Collaborators
Health and Medical Services, Helsana, Neomentum, Sanatorium Kilchberg AG, Design your life
Responsible party
Aureliano Crameri (Dr. phil., Zurich University of Applied Sciences) — Principal investigator
First posted
Jul 11, 2017
Start date
Jul 10, 2017
Primary completion
Jul 31, 2019
Completion
Jul 31, 2019
Last update
Jun 23, 2020

Study contacts

Agnes von Wyl, Prof
principal investigator · Zurich University of Applied Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion